Table 8.
Multivariate logistic regression analysis on factors associated with experiencing side effects of the vaccine.
Model | Unstandardised Coefficients | Standardised Coefficients | p-value | |
---|---|---|---|---|
B | Std. Error | Beta | ||
(Constant) | 6.224 | 0.848 | 0.000 | |
Age | −0.750 | 0.141 | −0.204 | <0.001 |
Gender | −0.266 | 0.214 | −0.048 | 0.215 |
Hypertension | −0.101 | 0.121 | −0.036 | 0.401 |
Diabetes mellitus | −0.392 | 0.239 | −0.173 | 0.324 |
Vaccination | −0.038 | 0.163 | −0.009 | 0.814 |
Rheumatoid arthritis | 0.592 | 0.216 | 0.322 | 0.068 |
Non inflammatory/mechanical RMDs | 0.543 | 0.094 | 0.327 | 0.059 |
Axial SpA | 0.214 | 0.101 | 0.611 | 0.143 |
Vasculitis | 0.094 | 0.032 | 0.021 | 0.856 |
SLE | 0.153 | 0.045 | 0.043 | 0.766 |
Disease Activity at time of vaccination | −0.231 | 0.453 | −0.238 | 0.496 |
Drug exposure | −0.043 | 0.022 | −0.032 | 0.231 |
Steroid | 0.674 | 0.119 | 0.491 | 0.623 |
Steroid dose | 0.083 | 0.084 | 0.045 | 0.322 |
TNF- inhibitors | 0.043 | 0.112 | 0.074 | 0.123 |
Methotrexate | 0.327 | 0.054 | 0.192 | 0.871 |
Azathioprine | 0.656 | 0.210 | 0.439 | 0.073 |
Hydroxychloroquine | 0.385 | 0.134 | 0.346 | 0.306 |
Rituximab | 0.270 | 0.097 | 0.231 | 0.198 |
Leflunomide | 0.328 | 0.178 | 0.411 | 0.174 |
Mycophenolate | 0.376 | 0.044 | 0.276 | 0.099 |
Sulfasalazine | 0.402 | 0.361 | 0.402 | 0.219 |
Cyclophosphamide | 0.199 | 0.472 | 0.338 | 0.111 |
Cyclosporine | 0.112 | 0.365 | 0.322 | 0.067 |
RMDs: rheumatic and musculoskeletal diseases; SpA: spondyloarthritis; SLE: systemic lupus erythematosus.